Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Sabra Health Care REIT reported Q3 2026 net income of $0.11 per diluted share and Normalized AFFO of $0.41 per share. The company updated its full-year 2026 guidance, raising its Normalized AFFO range to $1.600 - $1.610 per share, and highlighted $747.2 million in year-to-date investments with an 8.0% estimated yield.
Independence Realty Trust reported Q3 2026 financial results with net income of $25.1 million and Core FFO of $0.29 per share. The company highlighted 1.6% same-store NOI growth and provided an update on its pending $8 billion merger with Centerspace, which is expected to close in late 2026. Management noted improving leasing momentum with blended rent growth of 2.8% and steady occupancy of 95.0%.
Counterparty
Centerspace
Term
Q3 2026
“We are pleased with our solid third quarter results, with same-store NOI growth of 1.6% and Core FFO per share of $0.29. Leasing momentum continued to build during the quarter. New lease trade-outs improved 310 basis points year over year, driving blended rent growth of 2.8%, while average occupancy held steady at 95.0% and resident retention remained healthy at 60.5%.”
Scott Schaeffer, Chairman and Chief Executive Officer
“We believe IRT is well positioned for stronger growth in 2027 as concessions burn off, our Wi-Fi program continues to ramp, and supply-demand fundamentals improve. We are also making meaningful progress on integration planning for our pending merger with Centerspace, which we believe will only build on our strength.”
Scott Schaeffer, Chairman and Chief Executive Officer
Gaia, Inc. reported third quarter 2026 financial results, showing a 12% revenue decrease to $22.0 million as the company deliberately shifted away from lower ARPU regions and third-party reliance. Despite a net loss of $3.0 million, management highlighted a 20% improvement in member churn and expects to return to positive free cash flow in the fourth quarter.
Term
Q3 2026
“Our third quarter results reflect the successful completion of the reset we announced at the beginning of March—a deliberate move to reduce our revenue reliance on third parties and lower ARPU regions. As part of this shift to prioritize long-term value, we have largely eliminated discounting, with the sole exception of returning members acquired without meaningful marketing spend. We are already seeing traction from these disciplined choices, with member churn rate improving by more than 20% from the first to the third quarter. We remain confident that this focus on the quality of our direct member base is building a stronger, more sustainable foundation.”
Kiersten Medvedich, Chief Executive Officer of Gaia
“Over the last 60 days, our revenue has stabilized at a quarterly run rate around $21.0 million. We have compensated for this lower revenue by effectively reducing expenses, which has allowed our annualized gross profit per employee to continue growing to $827,000. As predicted, we expect to return to positive free cash flow during the fourth quarter, resuming the trend of nine consecutive quarters of positive free cash flow we delivered prior to our March reset.”
EverQuote reported record third quarter 2026 results with revenue growing 25% year-over-year to $218.1 million and net income of $18.2 million. The company exceeded its guidance across all key metrics, driven by strong demand in its automotive and home insurance verticals. Additionally, the board approved a new $50 million share repurchase program.
Term
Q3 2026
“We are generating record results across our key financial metrics as we successfully grow and deepen our relationships with our carrier and agent customers. Carriers continue to maintain strong underwriting profitability and an appetite for growth, and our team is executing seamlessly to meet this demand. As we build on our strong foundation to accelerate new product innovation and development, we believe EverQuote is uniquely positioned to help steward P&C insurance into the agentic AI era.”
Jayme Mendal, Chief Executive Officer of EverQuote
“We reported a record third quarter, delivering revenue growth of 25% year-over-year, highlighting the strength of our market position as a trusted growth partner for our customers. We are focused on accelerating product innovation and unlocking new possibilities to capitalize on the opportunities ahead. Our continued strong growth and execution are enabling us to invest in AI initiatives, while simultaneously generating strong cash flow, maintaining a fortress balance sheet and returning capital to shareholders.”
Joseph Sanborn, Chief Financial Officer and Chief Administrative Officer of EverQuote
Adeia Inc. reported Q3 2026 revenue of $80.2 million and GAAP net income of $2.3 million, while announcing the appointment of Dipti Vachani as its new CEO. The company signed eight license agreements during the quarter, including multi-year renewals with Charter and TCL, and updated its full-year 2026 revenue guidance to a range of $360 million to $390 million.
Term
Q3 2026
“I am honored to join Adeia at such an exciting time as AI is driving innovation in both media and semiconductors, and Adeia’s foundational technologies are at the heart of these trends.”
Dipti Vachani, chief executive officer of Adeia
“We remain confident in our ability to achieve the high-end of our revenue guidance range for 2026. However, we felt it prudent to adjust the range to reflect the potential impact to the extent certain of these deals are executed beyond the end of the year.”
Backblaze reported Q3 2026 financial results with total revenue of $46.7 million, up 26% year-over-year, driven by 47% growth in its B2 Cloud Storage segment. The company significantly improved its bottom line, narrowing its net loss to $2.4 million and achieving an Adjusted EBITDA margin of 33%.
Term
Q3 2026
“Q3 2026 was another strong quarter, with B2 revenue growth accelerating to 47% year over year, up from 28% a year ago, reflecting broad-based momentum across our customer base.”
ISQ Open Infrastructure Co Capital Raise of $29.5M
ISQ Open Infrastructure Company LLC issued and sold unregistered shares across multiple classes for total aggregate net consideration of approximately $29.5 million. The shares were sold to investors for cash and issued to independent directors for services rendered. The company also reported its monthly Transactional Net Asset Value (NAV) per share as of September 30, 2026.
Vertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, a 12% increase year-over-year, driven by strong demand for its cystic fibrosis therapies and new product launches. The company raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion. During the quarter, Vertex also completed the $9 billion acquisition of Crinetics Pharmaceuticals and secured a $4.5 billion term loan.
“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.”
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
“With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
Independent Bank Corp. filed an investor presentation to be used at the KBW 2026 Boston Bank Day on November 3, 2026. The presentation highlights the company's $25.0 billion in total assets and record operating EPS of $1.90 for the third quarter of 2026.
Travere Therapeutics reported Q3 2026 financial results, highlighted by $200.2 million in FILSPARI net product sales, representing 120% year-over-year growth. The company is advancing its Phase 3 HARMONY study of pegtibatinase with topline results expected in the second half of 2027 and plans to submit an IND for civorebrutinib by year-end.
“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
“As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
Outdoor Specialty Products, Inc. filed a Certificate of Designation with the Nevada Secretary of State to establish a new series of 100 shares of Series A Preferred Stock. This action was taken out of the company's existing 10,000,000 authorized shares of preferred stock. The filing defines the voting powers, preferences, and rights of this new series, though no shares were reported as issued or sold in this filing.
Jerash Holdings restructured the compensation for its CEO Choi Lin Hung and Chairman Ng Tsze Lun by terminating existing consulting agreements with their respective entities and entering into direct employment agreements. Both executives will receive a monthly base salary of HK$297,000 plus an end-of-year payment equal to one month's salary under the new arrangements effective November 1, 2026.
Bambusa Therapeutics Director Helmut Wolfgang Jeggle Buys $6M of Stock
Helmut Wolfgang Jeggle, Director, bought 375,000 shares of Bambusa Therapeutics, Inc. at $16.00 a share, worth $6M in total on Nov 2, 2026. Shares held after the trade: 9,264,301 (+4.2%).
10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors. Both will receive compensation under the company's Non-Employee Director Compensation Policy, including an annual cash retainer of $60,000 and a one-time restricted stock unit grant valued at $400,000.
Theriva Biologics Divestiture to Biossil Labs Inc.
Theriva Biologics completed the sale of its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Biossil Labs Inc. for an upfront payment of $350,000. Theriva is eligible for up to $91 million in regulatory and sales milestones plus royalties, while Biossil assumes all future development costs and responsibilities.
Southwest Airlines $1.25B Debt Financing with U.S. Bank Trust Company, National Association
Southwest Airlines Co. completed a public offering of $1.25 billion in senior notes, consisting of $600 million of 5.750% notes due 2029 and $650 million of 6.000% notes due 2031. The notes were issued under an existing shelf registration statement to provide the company with long-term debt financing.
Avis Budget Group's subsidiaries have issued a notice to redeem all $350 million of their outstanding 5.750% Senior Notes due July 2027. The redemption is scheduled for December 30, 2026, at a price of 100% of the principal amount plus accrued interest.
Jennifer L. Davis, a Class II director, notified AbbVie of her intent to resign from the Board of Directors effective November 2, 2026. Her departure follows her appointment as CEO of Align Technology, Inc. and is not due to any disagreement with the company.
Elme Communities approved the termination of retention agreements for CEO Paul McDermott, COO Tiffany Butcher, and CFO W. Drew Hammond as the company winds up its affairs. The officers will receive cash lump sum payments totaling approximately $7.75 million ($5.06M, $1.66M, and $1.03M respectively) effective November 6, 2026. Following the company's dissolution, Hammond and Butcher are expected to enter into consulting agreements with the Liquidating Trust.
Cormorant Asset Management LP sold 425,000 shares of Corbus Pharmaceuticals Holdings, Inc. at $4.10 a share, worth $1.74M in total on Oct 29, 2026. Shares held after the trade: 1,919,971 (-18.1%).
Shore Bancshares, Inc. reported net income of $16.8 million for the third quarter of 2026, up from $14.3 million in the same period of 2025. The company saw a significant increase in net interest income to $55.1 million, driven by higher interest on loans, while total assets grew to $6.45 billion as of September 30, 2026.
Syndax Pharmaceuticals reported a significant increase in total revenues to $221.0 million for the nine months ended September 30, 2026, compared to $103.6 million in the prior year, driven by product sales of REVUFORJ and NIKTIMVO. Despite higher revenues, the company recorded a net loss of $141.5 million for the period, though this was an improvement from the $217.4 million loss in 2025. The balance sheet was strengthened by the issuance of a $250 million convertible note.
Business First Bancshares Insider George W. Cummings III Sells $583K of Stock
George W. Cummings III sold 18,373 shares of Business First Bancshares, Inc. at $31.73 a share, worth $583K in total on Oct 29, 2026. Shares held after the trade: 165,372 (-10.0%).
Tactile Systems Technology reported Q3 2026 total revenue of $91.9 million, a 7% increase year-over-year driven by 13% growth in its core lymphedema product line. While gross margin expanded to 77%, net income decreased to $7.2 million from $8.2 million in the prior year due to increased operating expenses supporting growth initiatives.
Term
Q3 2026
“Our results underscore the strength and durability of our core lymphedema business, which delivered its fifth consecutive quarter of double-digit year-over-year revenue growth, while gross margin expanded for the 12th consecutive quarter.”
Sheri Dodd, Chief Executive Officer of Tactile Medical
“We are positioned to capture that opportunity through three connected strategic priorities: expanding access to care, creating value across the patient journey, and broadening treatment options.”
Sheri Dodd, Chief Executive Officer of Tactile Medical
Capital Southwest reported its second fiscal quarter 2027 results, highlighted by a record $391 million in originations and the formation of a new technology-focused joint venture, Desert Star, with Trinity Capital. The company generated pre-tax net investment income of $0.58 per share and maintained a total investment portfolio of $2.4 billion.
Term
Q2 2027
“Capital Southwest delivered the largest origination quarter in our history, with approximately $391 million of originations across 14 new and 16 existing portfolio companies. We also committed $25 million to Desert Star, a new joint venture with Trinity Capital. This new joint venture gives us access to the technology lending market in partnership with Trinity, allowing us to gain exposure through a granular portfolio of investments in an area where we have not historically focused.”
Michael Sarner, President and Chief Executive Officer
“Our portfolio continued to generate strong earnings for our shareholders, producing $0.58 of pre-tax net investment income per share. Reflecting the strength of our earnings profile, the Board of Directors again declared a regular quarterly dividend of $0.58 per share, of which $0.1934 per share will be paid for each of October, November and December 2026, and a supplemental quarterly dividend of $0.06 to be paid in December 2026.”
Michael Sarner, President and Chief Executive Officer
WhiteHawk Minerals Debt Financing Update with Capital One, National Association
WhiteHawk Minerals Corp.'s subsidiary entered into a third amendment to its existing credit agreement with Capital One and other lenders. The amendment modifies the agreement to permit the issuance of Series E and Series F Preferred Stock and removes references to Series D Preferred Stock.
Fifth Third Bancorp EVP & Chief HR Officer Megan D. Burkhart Sells $21.2K of Stock
Megan D. Burkhart, EVP & Chief HR Officer, sold 398 shares of Fifth Third Bancorp at $53.45 a share, worth $21.2K in total on Oct 29, 2026. Shares held after the trade: 175,349 (-0.2%).
Hershey Insider Hershey Trust Co Trustee in Trust for Milton Hershey School Sells $3.26M of Stock
Hershey Trust Co Trustee in Trust for Milton Hershey School sold 20,000 shares of Hershey Co at $160.45 to $165.67 a share (average $163.22) in 11 transactions, worth $3.26M in total between Oct 29, 2026 and Oct 30, 2026. Shares held after the trade: 466,119 (-1.2%).
National Presto Industries reported a significant increase in third quarter 2026 results, with net sales rising 25% to $144.3 million and net earnings jumping to $20.0 million. Performance was driven by a 31.3% sales surge in the Defense segment due to backlog shipments and a one-time $8.1 million operating profit in Housewares following a Supreme Court-mandated tariff refund.
Term
Q3 2026
“Defense segment sales for the quarter were up $29 million or 31.3% from those reported in the comparable 2025 quarter, reflecting increased shipments from backlog. Sales for the Housewares/Small Appliances segment dipped nominally by $469 thousand or 2.1%. Safety segment sales, although still nominal, increased by $296,000 or 88.9%, reflecting increased distribution of a broader line. The Defense segment’s operating earnings were up $7.1 million or 61.8% from third quarter 2025 earnings largely due to the additional volume referenced above, along with a more favorable mix and increased operating efficiencies. In contrast to the prior year’s loss, Housewares/Small Appliance segment’s operating earnings were $8.1 million. Most of those earnings were attributable to a refund of a portion of the tariffs the segment had paid that the Supreme Court declared unauthorized in its February decision. The Safety segment reported a loss as anticipated.”